CDK19: A Potential Drug Target and Biomarker for Cancer (G23097)

Target Name: CDK19

NCBI ID: G23097

CDK19

CDK19: A Potential Drug Target and Biomarker for Cancer

Introduction

CDK19 (CDK-8-like cyclin-dependent kinase) is a key regulator of cell cycle progression and has been implicated in various cellular processes, including cell growth, differentiation, and apoptosis. CDK19 plays a crucial role in the control of mitosis, as it regulates the distribution of chromosomes during the metaphase stage and promotes the association of the centromere with the microtubules of the spindle. Moreover, CDK19 is involved in the regulation of DNA replication, cell migration, and the establishment of tissue structures. Therefore, alterations in CDK19 function have been implicated in various diseases, including cancer.

CDK19 is a 22-kDa protein that consists of a 21 kDa catalytic domain and a 9 kDa non-catalytic domain. The catalytic domain contains a single catalytic active site and is responsible for the kinetic aspects of the reaction. The non-catalytic domain is involved in the regulation of the activity of the catalytic domain.

CDK19 is a protein that can interact with multiple targets, including histones, microtubules, and transcription factors. It has been shown that CDK19 can physically interact with histones, such as histone H3 and histone Y, and can also interact with microtubules, such as those of the centromere and the mitotic spindle. These interactions play a crucial role in the regulation of cellular processes, including cell cycle progression and the control of chromosome behavior during mitosis.

CDK19 has also been shown to interact with transcription factors, such as p53 and NF-kappa-B. These interactions can modulate the activity of these transcription factors and contribute to the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

CDK19 has been implicated in various diseases, including cancer. For example, studies have shown that CDK19 is involved in the regulation of chromosomal stability during cancer progression. In addition, altered CDK19 function has been implicated in the development of various types of cancer, including Breast, ovarian, and colorectal cancers.

CDK19 has also been shown to be a potential drug target in cancer. For example, inhibition of CDK19 has been shown to be effective in various types of cancer, including breast, ovarian, and colorectal cancers. In addition, CDK19 has been shown to be a biomarker for cancer, as its expression has been shown to be associated with the development of various types of cancer.

CDK19 has also been studied as a potential therapeutic approach for cancer. For example, small molecules that inhibit CDK19 have been shown to be effective in treating various types of cancer, including breast, ovarian, and colorectal cancers. In addition, CDK19 has also been shown to be a good candidate for targeted therapies, such as inhibitors of CDK19 kinetic activity or inhibitors of its interactions with transcription factors.

Conclusion

In conclusion, CDK19 is a protein that plays a crucial role in the regulation of cell cycle progression and has been implicated in various cellular processes, including cancer. Its function as a regulator of cell cycle progression and its involvement in the regulation of chromosomal stability make CDK19 a potential drug target and biomarker for cancer. The regulation of CDK19 function is also being targeted by small molecules, which have the potential to be therapeutic approaches for cancer treatment. Further research is needed to fully understand the role of CDK19 in cancer and to develop effective therapies based on its functions.

Protein Name: Cyclin Dependent Kinase 19

The "CDK19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets